Ascendis Pharma A/S (ASND) News Today $172.35 -0.80 (-0.46%) Closing price 04:00 PM EasternExtended Trading$172.33 -0.02 (-0.01%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASND Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Ascendis Pharma price target raised to $216 from $201 at BofAJune 10 at 12:02 PM | msn.comCantor Fitzgerald Weighs in on ASND FY2026 EarningsAscendis Pharma A/S (NASDAQ:ASND - Free Report) - Cantor Fitzgerald issued their FY2026 earnings estimates for Ascendis Pharma A/S in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek expects that the biotechnology company will earn $3.43 pJune 10 at 9:45 AM | marketbeat.comToth Financial Advisory Corp Buys Shares of 5,335 Ascendis Pharma A/S (NASDAQ:ASND)Toth Financial Advisory Corp purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 5,335 shares of the biotechnology company's stock, vJune 10 at 4:59 AM | marketbeat.comBank of America Raises Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $216.00Bank of America increased their price target on Ascendis Pharma A/S from $201.00 to $216.00 and gave the company a "buy" rating in a report on Monday.June 9 at 2:47 PM | marketbeat.comTransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH TrialJune 9 at 7:00 AM | globenewswire.comAscendis Pharma A/S (NASDAQ:ASND) Given Consensus Recommendation of "Buy" by BrokeragesShares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have earned an average rating of "Buy" from the fifteen analysts that are covering the stock, MarketBeat.com reports. Fifteen investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brJune 8 at 3:42 AM | marketbeat.comIs Ascendis Pharma Gaining or Losing Market Support?June 5, 2025 | benzinga.comBank of America Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) StockJune 5, 2025 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Two Sigma Investments LPTwo Sigma Investments LP lessened its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 78.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,915 shares of the biotechnology company's stock after sellingJune 4, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Up 8.6% - Should You Buy?Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Up 8.6% - Time to Buy?June 3, 2025 | marketbeat.comAscendis Pharma ADR Scores Relative Strength Rating UpgradeJune 3, 2025 | msn.comAscendis Pharma A/S (NASDAQ:ASND) Given New $201.00 Price Target at Bank of AmericaBank of America lifted their target price on Ascendis Pharma A/S from $196.00 to $201.00 and gave the company a "buy" rating in a research report on Tuesday.June 3, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Two Sigma Advisers LPTwo Sigma Advisers LP lowered its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 88.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,400 shares of the biotechnology company's stock after selling 41June 3, 2025 | marketbeat.comAscendis Pharma stock rises following FDA priority reviewJune 2, 2025 | investing.comAscendis Pharma Rises as FDA Grants Priority Review for Achondroplasia TreatmentJune 2, 2025 | msn.comFDA Accepts TransCon® CNP NDA for Priority ReviewJune 2, 2025 | globenewswire.comGAMMA Investing LLC Has $142.60 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)GAMMA Investing LLC lifted its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 15,593.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 91,490 shares of the biotechnology company'sJune 2, 2025 | marketbeat.comBank of America Corp DE Sells 6,037,189 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Bank of America Corp DE decreased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 99.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 26,383 shares of the biotechnology company's stock after selling 6,037,189 sharesJune 1, 2025 | marketbeat.comAscendis Pharma’s SWOT analysis: strong product pipeline drives stock potentialMay 27, 2025 | investing.comVoloridge Investment Management LLC Decreases Stake in Ascendis Pharma A/S (NASDAQ:ASND)Voloridge Investment Management LLC cut its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 24.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 298,996 shares of the biotechnology company's stoMay 23, 2025 | marketbeat.comWoodline Partners LP Has $43.73 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Woodline Partners LP increased its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 35.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 317,642 shares of the biotechnology company's stock afMay 22, 2025 | marketbeat.comZimmer Partners LP Has $13.34 Million Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)Zimmer Partners LP increased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 24.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,900 shares of the biotechnoMay 22, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Holdings Boosted by Vestal Point Capital LPVestal Point Capital LP grew its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 108.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 520,000 shares of the biotechnology company's stock afterMay 21, 2025 | marketbeat.comSoleus Capital Management L.P. Makes New $19.82 Million Investment in Ascendis Pharma A/S (NASDAQ:ASND)Soleus Capital Management L.P. purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 144,000 shares of the biotechnology compMay 21, 2025 | marketbeat.comTema Etfs LLC Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND)Tema Etfs LLC acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 19,040 shares of the biotechnology company's stock, valuMay 20, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of "Buy" from AnalystsShares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have earned a consensus recommendation of "Buy" from the fifteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Fifteen analysts have rated the stock with a buy recommendation. The average 12-month price oMay 16, 2025 | marketbeat.comMaven Securities LTD Sells 40,000 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Maven Securities LTD decreased its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 80.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,000 shares of the biotechnology company's stock after sellingMay 15, 2025 | marketbeat.comMoore Capital Management LP Cuts Position in Ascendis Pharma A/S (NASDAQ:ASND)Moore Capital Management LP decreased its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 50.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,000 shares of the biotechnology company's stock after selling 20,000 shaMay 15, 2025 | marketbeat.comBalyasny Asset Management L.P. Purchases New Position in Ascendis Pharma A/S (NASDAQ:ASND)Balyasny Asset Management L.P. purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 15,419 shares of the biotechnology compMay 15, 2025 | marketbeat.comAscendis Pharma Announces Long-Term Phase 2 Trial Data Demonstrating Sustained Efficacy and Safety of TransCon PTH in Adults with HypoparathyroidismMay 14, 2025 | nasdaq.comAscendis Pharma A/S's (ASND) "Overweight" Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and issued a $200.00 target price on shares of Ascendis Pharma A/S in a report on Monday.May 14, 2025 | marketbeat.comAscendis Pharma A/S (ASND): Among the Best Growth Stocks to Buy and Hold for the Long TermMay 13, 2025 | insidermonkey.comNew Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)May 13, 2025 | globenewswire.comJanus Henderson Group PLC Purchases 193,688 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Janus Henderson Group PLC lifted its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,380,382 shares of the biotechnology companMay 13, 2025 | marketbeat.comAscendis Pharma: New 4-Year Data Shows Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with HypoparathyroidismMay 13, 2025 | finanznachrichten.deNew 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with HypoparathyroidismMay 12, 2025 | globenewswire.comDriehaus Capital Management LLC Lowers Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Driehaus Capital Management LLC reduced its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 22.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 88,496 shares of the biotechnology company's stockMay 12, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Stake Lessened by Fred Alger Management LLCFred Alger Management LLC reduced its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 56.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 111,854 shares of the biotechnology coMay 11, 2025 | marketbeat.comCantor Fitzgerald Has Weak Outlook for ASND FY2025 EarningsAscendis Pharma A/S (NASDAQ:ASND - Free Report) - Stock analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for Ascendis Pharma A/S in a research note issued to investors on Tuesday, May 6th. Cantor Fitzgerald analyst L. Watsek now expects that the biotechnology companMay 10, 2025 | marketbeat.comMorgan Stanley Upgrades Ascendis Pharma A/S (NASDAQ:ASND) to "Overweight"Morgan Stanley raised Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $180.00 to $250.00 in a research report on Monday.May 7, 2025 | marketbeat.comBellevue Group AG Takes $344,000 Position in Ascendis Pharma A/S (NASDAQ:ASND)Bellevue Group AG acquired a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,500 shares of the biotechnology company's stock, valued at approximatelyMay 7, 2025 | marketbeat.comAlyeska Investment Group L.P. Acquires 40,000 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Alyeska Investment Group L.P. increased its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 34.8% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 155,000 shares of the biotechnology company's stock after buying an additional 40,000 shares duriMay 7, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Boosts Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)The Manufacturers Life Insurance Company grew its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 16.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 82,955 shares of the biotechnologyMay 7, 2025 | marketbeat.comStifel Financial Corp Has $2.35 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Stifel Financial Corp boosted its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 36.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,097 shares of the biotechnology company's stock after pMay 7, 2025 | marketbeat.comWedbush Equities Analysts Raise Earnings Estimates for ASNDAscendis Pharma A/S (NASDAQ:ASND - Free Report) - Equities research analysts at Wedbush boosted their FY2029 earnings per share (EPS) estimates for shares of Ascendis Pharma A/S in a research note issued to investors on Thursday, May 1st. Wedbush analyst Y. Zhong now anticipates that the biotechnMay 7, 2025 | marketbeat.comHere's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 YearsMay 7, 2025 | benzinga.comLaunch of New Drug Lifted Ascendis Pharma A/S (ASND) in Q1May 7, 2025 | msn.comAquatic Capital Management LLC Takes $230,000 Position in Ascendis Pharma A/S (NASDAQ:ASND)Aquatic Capital Management LLC acquired a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,674 shares of the biotechnology company's sMay 6, 2025 | marketbeat.comAscendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025May 5, 2025 | finance.yahoo.comMorgan Stanley Upgrades Ascendis Pharma A (ASND)May 5, 2025 | msn.com Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address ASND Media Mentions By Week ASND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASND News Sentiment▼0.790.68▲Average Medical News Sentiment ASND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASND Articles This Week▼127▲ASND Articles Average Week Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARGX News Today ONC News Today BNTX News Today TEVA News Today SMMT News Today GMAB News Today ITCI News Today RDY News Today MRNA News Today VTRS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASND) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ASND Stock Free ASND Stock Alerts